Anastasios Manessis, MD
Endocrinology, Diabetes & Metabolism · New York, NYNPI 1467615823
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $548,595 of the $656,431 with a category attached, or 83.6%. 60 manufacturers reported payments, led by Lilly USA, LLC at 27.4% of the total. 2025 is the largest year on record at $174,540, 2.1 times the $82,447 reported in 2019. Among endocrinology, diabetes & metabolism clinicians in NY with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 1,978 payments — averaging $331.87 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Lilly USA, LLC$180K
- Novo Nordisk$160K
- Ascendis Pharma Endocrinology Inc$73K
- Sanofi-aventis U.S. LLC$70K
- Mannkind Corporation$56K
- AstraZeneca$36K
- plus $81K from 54 others
Across 1,039 payments — averaging $3760.20 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Eli Lilly$2.6M
- Novo Nordisk AS$550K
- AbbVie$330K
- Sanofi US Services Inc.$134K
- Mannkind Corporation$111K
- Medtronic$83K
- plus $94K from 7 others
What the payments were for
- Consulting fees$35,1845%
- Speaking & faculty fees$548,59584%
- Travel & lodging$24,6244%
- Food & beverage$47,9577%
- Education$720%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- MOUNJARO$123,252
- JARDIANCE$75,409
- Ozempic$69,752
- RYBELSUS$66,707
- Yorvipath$59,312
- AFREZZA$53,632
- FARXIGA$34,294
- TZIELD$28,444
- SOLIQUA 100/33$22,673
- TOUJEO$16,341
- INVOKANA$12,315
- Tresiba$8,433
- MYCAPSSA$6,775
- UPLIZNA$5,175
- Thyquidity$3,379
- TEPEZZA$3,312
- Korlym$2,701
- Minimed 670G System$1,375
- SOMAVERT$880
- t:slim X2 insulin pump$800
How this compares
$656,431 in reported general payments places this provider in the 95th percentile of 804 endocrinology, diabetes & metabolism providers in New York.
See all endocrinology, diabetes & metabolism providers in New York →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| MounjaroTirzepatide | 1,281 | $1,664,142 |
| OzempicSemaglutide | 792 | $1,077,118 |
| JardianceEmpagliflozin | 704 | $777,866 |
| FarxigaDapagliflozin Propanediol | 440 | $469,923 |
| TrulicityDulaglutide | 267 | $381,867 |
| RybelsusSemaglutide | 148 | $243,113 |
| Tresiba Flextouch U-100Insulin Degludec | 365 | $241,633 |
| JanuviaSitagliptin Phosphate | 81 | $99,437 |
| Fiasp FlextouchInsulin Aspart (Niacinamide) | 114 | $88,237 |
| MycapssaOctreotide Acetate | 13 | $84,939 |
| Toujeo SolostarInsulin Glargine,hum.Rec.Anlog | 132 | $84,101 |
| Tresiba Flextouch U-200Insulin Degludec | 95 | $82,049 |
| AfrezzaInsulin Regular, Human | 22 | $77,095 |
| Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog | 87 | $74,137 |
| Omnipod 5 Dexg7g6 Pods (Gen 5)Insulin Pump Cart,auto,bt,g6/7 | 65 | $73,895 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCMounjaro, Trulicity | $180,068 | $2,046,0091,548 claims |
| Novo NordiskOzempic, Rybelsus, Novolog | $160,374 | $1,337,078979 claims |
| Boehringer IngelheimJardiance, Tradjenta, Synjardy Xr | $28,207 | $836,883767 claims |
| AstraZenecaFarxiga | $36,042 | $469,923440 claims |
| MerckJanuvia, Janumet | $300 | $130,582113 claims |
| Chiesi USA, Inc.Mycapssa | $51 | $84,93913 claims |
| Mannkind CorporationAfrezza | $56,242 | $77,09522 claims |
| Johnson & JohnsonInvokana | $12,327 | $71,87560 claims |
| AbbVieSynthroid | $1,358 | $38,431381 claims |
| Sanofi-aventis U.S. LLCSoliqua 100-33 | $69,716 | $35,11730 claims |
| AmgenProlia | $9,528 | $22,27213 claims |
| PfizerEliquis | $1,524 | $20,72717 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 804 endocrinology, diabetes & metabolism providers in New York.
Other endocrinology, diabetes & metabolism in New York
- John BilezikianNew York$809K
- Jason BakerNew York$427K
- Brian LevyNew York$417K
- Stuart WeissNew York$275K
- Priya JaisinghaniNew York$239K
- Henry GinsbergNew York$161K
- Recaredo BerbanoNew York$146K
- Beverly TchangNew York$120K
- Shira EytanNew York$96K
- Minisha SoodNew York$91K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.